Correction of Anticoagulant Therapy in Patients with Severe COVID-19 Virus Infection Using a Thrombodynamics Coagulation Assay.

Tatiana S VuimoSergey V TsarenkoElena V FilimonovaElena A SereginaSergey S Karamzin

Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2022)

The dosing LMWH under thrombodynamics control in severe patients with COVID-19 allows for a significant reduction in thrombotic complications. Long-term hypercoagulation revealed by thrombodynamics (3 and more days) is a strong predictor of thrombosis (AUC = 0.83).

Keyphrases

coronavirus disease
early onset
sars cov
venous thromboembolism
atrial fibrillation
high throughput
risk factors
drug induced
respiratory syndrome coronavirus
single cell